Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.verified

AGLE

Price:

$12.01

Market Cap:

$48.63M

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly kno...[Read more]

Industry

Biotechnology

IPO Date

2016-04-07

Stock Exchange

NASDAQ

Ticker

AGLE

The Enterprise Value as of November 2024 (TTM) for Aeglea BioTherapeutics, Inc. (AGLE) is -41964351.00

According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -41964351.00. This represents a change of -22.53% compared to the average of -54170269.41 of the last 4 quarters.

Aeglea BioTherapeutics, Inc. (AGLE) Historical Enterprise Value (quarterly & annually)

How has AGLE Enterprise Value performed in the past?

The mean historical Enterprise Value of Aeglea BioTherapeutics, Inc. over the last ten years is 121.43M. The current -41964351.00 Enterprise Value has changed -3555.73% with respect to the historical average. Over the past ten years (40 quarters), AGLE's Enterprise Value was at its highest in in the September 2021 quarter at 503.52M. The Enterprise Value was at its lowest in in the June 2023 quarter at -187908026.88.

Quarterly (TTM)
Annual

Average

121.43M

Median

75.70M

Minimum

-5153996.25

Maximum

335.39M

Aeglea BioTherapeutics, Inc. (AGLE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 93.40%

Maximum Annual Enterprise Value = 335.39M

Minimum Annual Increase = -1492.55%

Minimum Annual Enterprise Value = -5153996.25

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20227.69M-97.45%
2021302.19M-9.90%
2020335.39M45.88%
2019229.91M72.21%
2018133.50M93.40%
201769.03M-1439.28%
2016-5153996.25-106.26%
201582.38M28.68%
201464.02M-1492.55%

Aeglea BioTherapeutics, Inc. (AGLE) Average Enterprise Value

How has AGLE Enterprise Value performed in the past?

The current Enterprise Value of Aeglea BioTherapeutics, Inc. (AGLE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

215.09M

5-year avg

201.73M

10-year avg

121.43M

Aeglea BioTherapeutics, Inc. (AGLE) Enterprise Value vs. Peers

How is AGLE’s Enterprise Value compared to its peers?

Aeglea BioTherapeutics, Inc.’s Enterprise Value is less than Edgewise Therapeutics, Inc. (3.01B), less than Ikena Oncology, Inc. (45.73M), less than Design Therapeutics, Inc. (290.40M), less than Xilio Therapeutics, Inc. (-13633399.00), less than Eliem Therapeutics, Inc. (119.64M), less than eFFECTOR Therapeutics, Inc. (4.74M), less than Landos Biopharma, Inc. (42.62M), less than Apexigen, Inc. (-5121682.00), less than Navidea Biopharmaceuticals, Inc. (-2504975.00), less than Angion Biomedica Corp. (22.43M), less than SAB Biotherapeutics, Inc. (24.24M), less than Senti Biosciences, Inc. (34.09M), less than Cingulate Inc. (5.36M), less than Bellicum Pharmaceuticals, Inc. (-5130674.00), less than Hillstream BioPharma, Inc. (1.48M), less than Neoleukin Therapeutics, Inc. (-6333315.00), less than CytomX Therapeutics, Inc. (39.67M), less than Assembly Biosciences, Inc. (68.59M), less than Instil Bio, Inc. (165.40M), less than Nuvation Bio Inc. (923.54M), less than Applied Molecular Transport Inc. (-5743713.00), less than Catalyst Biosciences, Inc. (19.42M), less than Aileron Therapeutics, Inc. (35.86M), less than Bio-Path Holdings, Inc. (3.00M), less than Benitec Biopharma Inc. (175.91M),

Build a custom stock screener for Aeglea BioTherapeutics, Inc. (AGLE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aeglea BioTherapeutics, Inc. (AGLE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aeglea BioTherapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aeglea BioTherapeutics, Inc. (AGLE)?

What is the 3-year average Enterprise Value for Aeglea BioTherapeutics, Inc. (AGLE)?

What is the 5-year average Enterprise Value for Aeglea BioTherapeutics, Inc. (AGLE)?

How does the current Enterprise Value for Aeglea BioTherapeutics, Inc. (AGLE) compare to its historical average?